ArticleThe Journal of infection2021
Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: Results of a large multicenter study.
Article in The Journal of infection, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 8 citations in OpenAlex.
- A Gaussia luciferase reporter assay for the evaluation of coronavirus Nsp5/3CLpro activity.Scientific reports · 2024Article
- Variability of Steroid Prescription for COVID-19 Associated Pneumonia in Real-Life, Non-Trial Settings.Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) · 2022Article
- WHO Ordinal Scale and Inflammation Risk Categories in COVID-19. Comparative Study of the Severity Scales.Journal of general internal medicine · 2022Article
- The Use of Corticosteroids or Tocilizumab in COVID-19 Based on Inflammatory Markers.Journal of general internal medicine · 2022Article
- High-dose steroids for the treatment of severe COVID-19: a new therapeutic tool?Internal and emergency medicine · 2021Article
- Wuhan to World: The COVID-19 Pandemic.Frontiers in cellular and infection microbiology · 2021Review
- Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021.Frontiers in pharmacology · 2021Review
Corrections and comments
- Comment on
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.